Evotec Investor Day Presentation Deck
Discovery
Molecule
Various ND ¹)
ND 1)
ND 1)
INDY inhibitor
Various
ND¹)
ND ¹)
ND 1)
ND ¹)
ND ¹)
evotec
ND 1)
TargetPicV
Various
Various
ND 1)
ND 1)
Various
Various
Various ND ¹)
ND ¹)
ND ¹)
Various
PAGE 22
Follow-on discovery projects are progressing rapidly
Partnership research and discovery portfolio
Therapeutic Area/Indication
Nephrology
Nephrology
PCOS
Metabolic
Oncology
Oncology
Oncology - Colorectal cancer
Oncology - DNA damage response
Novel antibiotics
Novel antibiotics
Anti-bacterial
Antiviral
Anti-infectives
All indications
Dermatological diseases
Facioscapulohumeral Dystrophy
Immunology & Inflammation - Tissue fibrosis
Fibrotic disease
Immunology & Inflammation
Inflammatory
Cancer
Internal: Oncology, CNS, Metabolic, Pain & Inflammation
1) Not disclosed
Partner
AstraZeneca
Fryze
VIFOR
PHARMA
Bristol Myers Squibb
M
•O
BREAKPOINT
indivumed
The Mark Foundation"
for Cancer Research
HELMHOLTZ
RESEARCH FOR GRAND CHALLENGES
GARDP
celmatix
THERAPEUTICL
FORGE
Therapeutics
Faplogen
28
facio
therapies
ucb
almirall
Inha
Pfizer
•
evotec >5 programmes
encon Galápagos
LABS91 LAB031 LAB10X
Immunitas
Aeovian
PHARMACEUTICALS
>40 further programmes
Discovery
Pre-clinical
Phase I
Phase II
Phase IIIView entire presentation